Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma - Lim - 2017 - Cancer - Wiley Online Library
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management - ScienceDirect
Clinical Development of BRAF plus MEK Inhibitor Combinations: Trends in Cancer
![PDF] Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c096f23cc88dea1f4635eb820fb4548ab1056b0f/4-Figure1-1.png "PDF] Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Semantic Scholar")
PDF] Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Semantic Scholar
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial - The Lancet Oncology
The role of BRAF
Frontiers | BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
Mechanisms of intrinsic resistance to BRAF-MEK inhibitors. Coexistent... | Download Scientific Diagram
Overcoming Resistance to BRAF and MEK Inhibitors by Simultaneous Suppression of CDK4 | IntechOpen
Systemic treatment for BRAF-mutant melanoma: where do we go next? - The Lancet Oncology
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma | Oncogene
Dabrafenib plus Trametinib: Two Kinase Inhibitors Used in Combination to Target Different Parts of the MAPK Pathway | Personalized Medicine in Oncology
Frontiers | Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
Cancers | Free Full-Text | Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
BRAF Alterations in Primary Brain Tumors - Stefania Maraka - Discovery Medicine
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma | Nature Reviews Clinical Oncology
MEK inhibitors for the treatment of non-small cell lung cancer | Journal of Hematology & Oncology | Full Text
Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms | Bentham Science
Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI
Figure 1 from Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. | Semantic Scholar
Biomarkers May Predict Response to BRAF and MEK inhibitors in Malignant Melanoma – OncoPrescribe
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management - Livingstone - Chinese Clinical Oncology
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review - ScienceDirect
